Program
tezepelumab
Also written as “Tezepelumab”, “Experimental: Tezepelumab” and “MEDI9929”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic · Nasal Polyps · Rhinosinusitis, led by 3 companies.
Drug pageTezepelumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 288 open or running | phase 4since Mar 17, 2022 | Jul 30, 2013 | Jan 13, 2027phase 3 · NCT06706817 |
| Amgenits history only | 50 open or running | phase 2since Jan 10, 2019 | Sep 18, 2008 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | Dec 2028phase 3 · NCT07302516 |
Also a collaborator on its studies: Fortrea and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 13 earlier studies, Jul 30, 2013 to Jul 29, 2019.
- Jun 9, 2015Named tezepelumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, MEDI9929
- Apr 23, 2020Phase 1 study in Healthy SubjectsNCT04362410 · 48 enrolled · China
- Dec 2, 2020Phase 1 study in AsthmaNCT04673630 · 18 enrolled · Hungary, South Africa, United Kingdom
- Feb 18, 2021Phase 3 study in Nasal PolypsNCT04851964 · 416 enrolled · United States, Canada, China and more
- Aug 23, 2021Phase 3 study in Moderate to Severe AsthmaNCT05062759 · 70 enrolled · United States
- Jan 27, 2022Phase 3 study in AsthmaNCT05274815 · 305 enrolled · United States, Argentina, Belgium and more
- Mar 17, 2022Phase 4 study in AsthmaNCT05329194 · 286 enrolled · United States
- May 26, 2022Phase 3 study in AsthmaNCT05398263 · 125 enrolled · United States, Brazil, Canada and more
- Oct 13, 2022Phase 3 study in Eosinophilic EsophagitisNCT05583227 · 368 enrolled · United States, Australia, Austria and more
- Jul 20, 2023Phase 3 study in AsthmaNCT06023589 · 231 planned · United States, Argentina, Brazil and more
- Jun 10, 2024Phase 3 study in AsthmaNCT06473779 · 310 enrolled · United States, Argentina, Belgium and more
- Nov 7, 2024Phase 3 study in RhinosinusitisNCT06706817 · 181 enrolled · United States, Bulgaria, Canada and more
- Mar 3, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT06883305, NCT06878261
- Nov 25, 2025Phase 3 study in AsthmaNCT07363642 · 400 planned · China
- Mar 24, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07520162 · 230 planned · China
Ahead
- Jan 13, 2027Primary completion: phase 3 study in RhinosinusitisNCT06706817
- Jun 25, 2027Primary completion: phase 3 study in AsthmaNCT06473779
- Feb 7, 2028Primary completion: phase 3 study in AsthmaNCT07363642
- Mar 1, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07520162
TargetBeta
“Thymic stromal lymphopoietin inhibitor; Thymic stromal lymphopoietin inhibitor”ChEMBL 37, by rule
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| felcorekibart | GlaxoSmithKline | phase 3 | 9 |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 7 |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 7 |
| WIN378rule | windward-bio | phase 2 | 2 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 28 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07520162Chronic Rhinosinusitis With Nasal Polyps · China | 3 | Recruiting | Mar 1, 2028 | 230 |
| NCT07363642Asthma · China | 3 | Recruiting | Feb 7, 2028 | 400 |
| NCT06883305Pulmonary Disease, Chronic Obstructive · United States, Brazil, Canada and more | 3 | Recruiting | Mar 13, 2029 | 990 |
| NCT06878261Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | Mar 13, 2029 | 990 |
| NCT06706817Rhinosinusitis · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | Jan 13, 2027 | 181 |
| NCT06473779Asthma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jun 25, 2027 | 310 |
| NCT06023589Asthma · United States, Argentina, Brazil and more | 3 | Recruiting | May 31, 2028 | 231 |
| NCT05583227Eosinophilic Esophagitis · United States, Australia, Austria and more | 3 | Active, not recruiting | Jul 14, 2026 | 368 |
| NCT05398263Asthma · United States, Brazil, Canada and more | 3 | Terminated | Mar 24, 2025 | 125 |
| NCT05329194Asthma · United States | 4 | Completed | Oct 1, 2025 | 286 |
| NCT05274815Asthma · United States, Argentina, Belgium and more | 3 | Completed | Sep 9, 2024 | 305 |
| NCT05062759Moderate to Severe Asthma · United States | 3 | Completed | Mar 21, 2022 | 70 |
| NCT04851964Nasal Polyps · United States, Canada, China and more | 3 | Completed | Sep 23, 2024 | 416 |
| NCT04673630Asthma · Hungary, South Africa, United Kingdom | 1 | Completed | Sep 27, 2022 | 18 |
| NCT04362410Healthy Subjects · China | 1 | Completed | Oct 9, 2020 | 48 |
| NCT04039113Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more | 2 | Completed | Nov 10, 2023 | 337 |
| NCT03989544Asthma · Germany | 1 | Completed | Dec 30, 2019 | 315 |
| NCT04048343Asthma · Japan | 3 | Completed | Mar 18, 2021 | 65 |
| NCT03968978Asthma · United States, Canada, Japan and more | 3 | Completed | Jun 5, 2020 | 216 |
| NCT03927157Asthma · China, Philippines, South Korea | 3 | Completed | May 24, 2024 | 405 |
| NCT03706079Asthma · United States, Argentina, Australia and more | 3 | Completed | Oct 26, 2021 | 951 |
| NCT03688074Asthma · United States, Canada, Denmark and more | 2 | Completed | Nov 16, 2020 | 116 |
| NCT03406078Asthma · United States, Argentina, Germany and more | 3 | Completed | Sep 25, 2020 | 150 |
| NCT03347279Asthma · United States, Argentina, Australia and more | 3 | Completed | Sep 8, 2020 | 1,061 |
| NCT02525094Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | May 9, 2016 | 113 |
| NCT02512900Asthma · Poland | 1 | Completed | May 17, 2016 | 21 |
| NCT02054130Asthma · United States, Bulgaria, Czechia and more | 2 | Completed | Dec 12, 2016 | 584 |
| NCT01913028Healthy · Japan | 1 | Completed | Jan 2014 | 64 |
How it is read
Names in the registry
- “Tezepelumab”, 23 entries
- “Experimental: Tezepelumab”, 4 entries
- “MEDI9929”, 2 entries
- “tezepelumab (Arm1&Arm2)”, 1 entry
- “Tezepelumab Dose 1”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 20 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Dermatitis, Atopic, 3 studies
- Nasal Polyps, 2 studies
- Rhinosinusitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.